Ichthyosis Pipeline Analysis Report 2026

Ichthyosis is a group of rare genetic skin disorders characterized by chronic dry, scaly skin, significantly impacting patients’ quality of life. Globally, ichthyosis vulgaris affects approximately 1 in 100-250 individuals, while severe syndromic forms like Netherton syndrome are far rarer. The ichthyosis pipeline analysis highlights emerging disease-modifying therapies, including protein-targeted biologics and gene-based approaches, which aim to correct underlying molecular defects, offering unprecedented opportunities for treatment innovation in this underserved dermatology segment.

Report Coverage

The Ichthyosis Pipeline Analysis Report gives comprehensive insights into ichthyosis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Ichthyosis. The ichthyosis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The ichthyosis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with ichthyosis treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to Ichthyosis.

Ichthyosis Pipeline Outlook

Ichthyosis is a rare skin disease characterized by persistent scaly skin and excessive skin scaling due to abnormal keratinization. This genetic ichthyosis results from mutations affecting the skin barrier, leading to hyperkeratosis, dryness, and inflammation. It is commonly presented at birth in congenital ichthyosis and reflects an underlying keratin disorder.

Ichthyosis treatment focuses on improving skin hydration and reducing skin scaling through emollients, keratolytics, and retinoids. Advanced ichthyosis therapy aims to restore the skin barrier and alleviate ichthyosis symptoms, enhancing overall ichthyosis care and patient quality of life. In January 2026, researchers introduced a novel CRISPR-based therapy targeting genetic ichthyosis, marking progress in the ichthyosis treatment pipeline. The topical gene-editing approach restores skin barrier function in congenital ichthyosis, demonstrating potential as a one-time ichthyosis therapy for this dry skin disorder.

Ichthyosis Epidemiology

The pipeline is advancing with a focus on targeted therapies addressing disease incidence and unmet needs. According to Maritska, Ziske et al., 2024, ichthyosis affects 5-10 per 100,000 people globally, while as per the Cleveland Clinic, Harlequin ichthyosis occurs in approximately 1 in 300,000-500,000 births in the United States. Current research emphasizes epidermal disorder, ichthyosis management, and skin hydration strategies. Emerging approaches also address dermatology rare conditions and cornified skin abnormalities, strengthening ichthyosis support frameworks. Overall, pipeline progress reflects increasing clinical focus and epidemiological demand.

Ichthyosis - Pipeline Therapeutic Assessment

This section of the report covers the analysis of Ichthyosis Drug candidates based on several segmentations, including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase 1)
• Preclinical and Discovery Stage Products

By Drug Class

The ichthyosis pipeline analysis report covers 50+ drug analyses based on drug classes:

• Small Molecules
• Monoclonal Antibodies
• Peptides

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration:

• Oral
• Parenteral
• Others

Ichthyosis Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II with 33%, covers a major share of the total Ichthyosis clinical trials, reflecting strong mid-stage clinical validation and accelerating therapeutic advancement. Phase I at 24% supports early innovation and safety profiling. Phase III with 19% strengthens late-stage commercialization potential. Phase IV with 14% enhances post-marketing evidence. Early phase I at 10% contributes to exploratory research, collectively driving sustained market growth and treatment innovation.

Ichthyosis Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the ichthyosis pipeline analysis include monoclonal antibodies, small molecules, and peptides. The ichthyosis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for ichthyosis. Protease inhibitor-based therapies are emerging as a promising drug class in the ichthyosis pipeline to address underlying skin barrier dysfunction. For instance, RVB-003 by ResVita Bio is under investigation for Netherton syndrome. It acts by inhibiting KLK5/7 protease activity, thereby reducing inflammation and restoring skin barrier integrity, offering a novel targeted therapeutic approach.

Ichthyosis Clinical Trials - Key Players

The report for the ichthyosis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed ichthyosis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in Ichthyosis clinical trials:

• Azitra Inc.
• BioCryst Pharmaceuticals
• GlaxoSmithKline
• Janssen Scientific
• Quoin Pharmaceuticals
• Biocodex
• Kerecis Ltd.
• Patagonia Pharma
• Crown Laboratories, Inc.
• Bristol Myers Squibb

Ichthyosis - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for ichthyosis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of Ichthyosis Drug candidates.

Drug: QRX003, 4% Lotion

QRX003, 4% Lotion is an investigational topical therapy developed for the treatment of Netherton syndrome, a rare genetic form of ichthyosis characterized by severe skin barrier dysfunction and inflammation. The lotion is designed to deliver a broad-spectrum serine protease inhibitor directly to the skin to help restore barrier integrity, reduce inflammation, and improve clinical symptoms associated with excessive protease activity. The therapy is currently being evaluated in a Phase II/III interventional clinical study assessing safety, tolerability, and efficacy in affected patients. QRX003 is being developed by Quoin Pharmaceuticals as part of its rare dermatology pipeline focused on genetic skin disorders.

Drug: Gentamicin

Gentamicin injectable solution is being evaluated in a Phase 2 clinical trial sponsored by University Hospital, Toulouse, for the treatment of Ichthyosis. The study examines the efficacy and safety of intravenous gentamicin, which enables stop codon readthrough to restore full-length protein production. The drug is being administered once weekly at 10 mg/kg for three months. The objective is to assess the reduction in scaling and erythema severity at three months. The study is expected to be completed in April 2027, with ongoing safety monitoring of renal and auditory functions.

Drug: ATR-01

ATR-01 is being developed by Azitra Inc. for the treatment of ichthyosis vulgaris. The preclinical study is evaluating safety, pharmacological activity, and effective delivery of filaggrin to restore the impaired skin barrier. The drug is a topical live biotherapeutic utilizing an engineered strain of S. epidermidis (ATR01-616) that is secreting functional human filaggrin directly into the stratum corneum. It is improving hydration and reducing transepidermal water loss. The program is progressing toward IND submission and is expected to enter early clinical development by 2026.

Key Questions Answered in the Ichthyosis Pipeline Insight Report

• Which companies/institutions are leading ichthyosis drug development?
• Which company is leading the ichthyosis pipeline development activities?
• What is the current ichthyosis commercial assessment?
• What are the opportunities and challenges present in the ichthyosis pipeline landscape?
• What is the efficacy and safety profile of ichthyosis pipeline drugs?
• Which company is conducting major trials for ichthyosis drugs?
• Which companies/institutions are involved in ichthyosis collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in ichthyosis?

Reasons To Buy This Report

The Ichthyosis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for ichthyosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into ichthyosis collaborations, regulatory environments, and potential growth opportunities.